Ignite Creation Date:
2025-12-25 @ 2:02 AM
Ignite Modification Date:
2026-02-25 @ 6:30 PM
Study NCT ID:
NCT03948360
Status:
UNKNOWN
Last Update Posted:
2019-05-13
First Post:
2018-11-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety Study of a Novel Wearable Phototherapy System for the Management of Acute Burn Wounds
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D002056', 'term': 'Burns'}, {'id': 'D014947', 'term': 'Wounds and Injuries'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D059039', 'term': 'Standard of Care'}], 'ancestors': [{'id': 'D019984', 'term': 'Quality Indicators, Health Care'}, {'id': 'D011787', 'term': 'Quality of Health Care'}, {'id': 'D006298', 'term': 'Health Services Administration'}, {'id': 'D017530', 'term': 'Health Care Quality, Access, and Evaluation'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'DEVICE_FEASIBILITY', 'interventionModel': 'SEQUENTIAL', 'interventionModelDescription': 'The study model is sequential. Arm I will consist of the first 3 participants, with each participant receiving LIMB phototherapy over standard of care (SOC). The subsequent participants will comprise Arm II, with each participant to receive only LIMB phototherapy without standard of care. Dose modifications of the phototherapy can be made in Arm II, and will be determined based on any treatment-related adverse events observed in Arm I. Up to 12 participants in total will be enrolled.'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 12}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2017-09-07', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-05', 'completionDateStruct': {'date': '2019-12-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2019-05-10', 'studyFirstSubmitDate': '2018-11-15', 'studyFirstSubmitQcDate': '2019-05-10', 'lastUpdatePostDateStruct': {'date': '2019-05-13', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2019-05-13', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-12-31', 'type': 'ESTIMATED'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Change in Pain as Assessed by Checklist Pain Behavior Scale', 'timeFrame': 'up to 7 days', 'description': "To evaluate the change in participant's pain score during LIMB phototherapy treatment. Pain assessments taken daily at dressing change."}], 'primaryOutcomes': [{'measure': 'Occurrence of Adverse Events from LIMB Phototherapy as Assessed by CTCAE v4.0', 'timeFrame': 'up to 7 days', 'description': 'To evaluate the occurrence of adverse events (treatment-related or otherwise) from LIMB phototherapy from the time of device application up to 7 days. Reporting consistent with CTCAE v4.0. Duration of LIMB phototherapy can be shortened per discretion of treating Investigator.'}], 'secondaryOutcomes': [{'measure': 'Change in Bioburden assessed through Wound Culture', 'timeFrame': 'up to 7 days', 'description': 'To evaluate the effect of LIMB phototherapy on microbial bioburden. Wound culture specimens are collected at each daily dressing change to measure the change in microbial bioburden when compared to baseline.'}]}, 'oversightModule': {'isUsExport': False, 'isFdaRegulatedDrug': False, 'isUnapprovedDevice': True, 'isFdaRegulatedDevice': True}, 'conditionsModule': {'keywords': ['acute burn, thermal injury, wound, phototherapy, wound healing, antimicrobial'], 'conditions': ['Burn Wound']}, 'descriptionModule': {'briefSummary': 'The primary purpose of this first-in-human, early feasibility study is to assess safety and feasibility of the Low-Irradiance Monochromatic Biostimulation (LIMB) System as a phototherapeutic intervention for the management of acute burn wounds. The prototype LIMB device will be evaluated for the occurrence of adverse events (treatment-related or otherwise) of the LIMB System, a portable, wearable, light-emitting system developed by Rogers Sciences, Inc. (RSI). The device will be administered in the small feasibility pilot to confirm design, usability and operating specifications that will inform procedures and endpoints of a subsequent large, multicenter clinical trial.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT'], 'maximumAge': '21 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Patients receiving care at Shriners Hospitals for Children-Boston for a skin tissue injury.\n* Patients who have at least one wound with exposed area sufficient, in the Investigator's opinion, to receive LIMB therapy.\n* Willing and able to adhere to daily LIMB therapy protocol.\n\nExclusion Criteria:\n\n* Patients deemed not medically stable by the treating Investigator.\n* Patients with clinical signs and symptoms of systemic infection at baseline.\n* Patients with burn wounds limited to their head and genitalia.\n* Patients who, in the opinion of the Investigator, will not require daily dressing changes.\n* Patients receiving photosensitizing agents that result in cutaneous phototoxicity prior to enrollment. Patients who have received one or more of the following photosensitizers cannot be enrolled into the study: photofrin, amiodarone, chloropromazine, fluoroquinolone antibiotics, thiazide diuretics, quinine, demethylchlortetracycline, psoralens, nalidixic acid, tetracycline, naproxen.\n* Patients currently enrolled or participating in another investigational device, drug or biological trial within 30 days of the Screening Visit.\n* Patients currently receiving any bandages or devices containing silver compounds.\n* Patients on a ventilator, who have fluid resuscitation or are in any terminal condition."}, 'identificationModule': {'nctId': 'NCT03948360', 'briefTitle': 'Safety Study of a Novel Wearable Phototherapy System for the Management of Acute Burn Wounds', 'organization': {'class': 'INDUSTRY', 'fullName': 'Rogers Sciences Inc.'}, 'officialTitle': 'A First-In-Human Pilot Study of a Novel Wearable Phototherapy System for the Management of Acute Burn Wounds', 'orgStudyIdInfo': {'id': 'BOS1705'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'LIMB Phototherapy with SOC', 'description': 'Arm I: The first 3 participants enrolled will receive standard of care therapy under the Low-Irradiance Monochromatic Biostimulation (LIMB) phototherapy device.', 'interventionNames': ['Device: Low-Irradiance Monochromatic Biostimulation (LIMB) Device', 'Other: Standard of Care']}, {'type': 'EXPERIMENTAL', 'label': 'LIMB Phototherapy without SOC', 'description': 'Arm II: The subsequent participants will receive only the Low-Irradiance Monochromatic Biostimulation (LIMB) phototherapy device without standard of care.', 'interventionNames': ['Device: Low-Irradiance Monochromatic Biostimulation (LIMB) Device']}], 'interventions': [{'name': 'Low-Irradiance Monochromatic Biostimulation (LIMB) Device', 'type': 'DEVICE', 'description': 'The LIMB System is a portable and wearable phototherapeutic system that consists of a Light Patch and Power Pack. The Power Pack delivers power to the Light Patch, which attaches to the participant and emits blue spectrum (405nm low-irradiance) light. The Light Patch contains an array of thin optical arrays that evenly illuminate the surface. The Power Pack is powered by a Lithium Thionyl Chloride (Li-SOCI2) battery.', 'armGroupLabels': ['LIMB Phototherapy with SOC', 'LIMB Phototherapy without SOC']}, {'name': 'Standard of Care', 'type': 'OTHER', 'description': 'Standard of care therapy as defined for this clinical trial is standard gauze dressing soaked in Sulfamylon (mafenide acetate) solution.', 'armGroupLabels': ['LIMB Phototherapy with SOC']}]}, 'contactsLocationsModule': {'locations': [{'zip': '02114', 'city': 'Boston', 'state': 'Massachusetts', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Robert L Sheridan, MD', 'role': 'CONTACT', 'email': 'rsheridan@partners.org', 'phone': '617-722-3000'}], 'facility': 'Shriners Hospitals for Children-Boston', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}], 'overallOfficials': [{'name': 'Robert L. Sheridan, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Shriners Hospitals for Children-Boston'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Rogers Sciences Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}